Please assess the completion status of the following clinical trial:

Trial Title: Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with inflammatory bowel disease who on are stable doses of infliximab or adalimumab for at least 3 months who experience a secondary loss of response to the medication based on clinical symptoms.~* Presence of at least one objective marker of active disease: active disease based on endoscopy, elevated fecal calprotectin or serologic markers of inflammation (C-reactive protein or sedimentation rate).~* Crohn's patients have a Harvey Bradshaw index \>5~* Ulcerative colitis patients have a Ulcerative Colitis Clinical Score \> 5~* Have an undetectable or inadequate trough level of infliximab or adalimumab and detectable ATI or ADA.~* Oral corticosteroid therapy is allowed. (prednisone at a stable dose ≤30 mg/day, budesonide at a stable dose ≤9 mg/day, or equivalent steroid) provided that the dose has been stable for the 4 weeks immediately prior to enrollment if corticosteroids have recently been initiated~Exclusion Criteria:~* Previous noncompliant with medications~* \< 18 years of age or \>80 years of age.~* Congestive heart failure~* Abnormal liver tests alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 2 × the upper limit of normal (ULN) or leucopenia WBC count \<3 × 109/L~* Pregnant or planning on becoming pregnant.~* Active tuberculosis or hepatitis B infection~* Any cancer within the past 5 years. (Exception non-melanomatous skin cancer.)~* Receiving any immunomodulator therapy within the past 3 months~* Evidence of or treatment for C. difficile infection within 60 days or other intestinal pathogen within 30 days prior to enrollment~* Clinically significant extra-intestinal infection (e.g., pneumonia, pyelonephritis) within 30 days of the initial screening visit~* Any live vaccinations within 30 days prior to study drug administration except for the influenza vaccine~* Any identified congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, human immunodeficiency virus \[HIV\] infection, organ transplantation)~* Any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise patient safety~* Unable to give own informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Immunomodulator (Type: EXPERIMENTAL): Azathioprine, 6 mercaptopurine or methotrexate.

Based on this trial design, predict the completion outcome and termination type (if applicable).